Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

ements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and unc
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... 2014  A substantial share of pharmacy and ... therapies are included in formularies—say patient support resources ... new Manhattan Research study, Taking the Pulse® ... that P&T committee members in hospitals, managed care ... set a high bar for these programs, requiring ...
(Date:7/31/2014)... -- Lazarus Effect, a medical device company focused on ... of blood clots, announced the closing of a $5 ... commercialization of several approved Lazarus Effect devices, as well ... Cover™ in the United States . ... value of our novel, platform technology as well as ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Lazarus Effect Closes $5 Million Financing 2
... FRISCO, Texas, March 15, 2012  OxySure® Systems, Inc. ... easy-to-use emergency oxygen solutions with its "oxygen from ... into a Supplier Agreement ("Agreement") with W.W. Grainger, ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In ...
... According to a national survey of independent pharmacists, ... drugstores and consumers who changed pharmacies. Independent pharmacists say ... ease, and still have many choices despite the absence ... This survey reveals significant upsides to preferred pharmacy ...
Cached Medicine Technology:OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3New Survey: Walgreens' Customers Flock to Independent Pharmacies 2
(Date:7/31/2014)... 2014) If you have asthma, you may have an ... you recognize and respond to changes and understand when symptoms ... the green zone, you,re doing well, yellow means your asthma ... require urgent care. New guidelines are now available to help ... into green and away from the red zone. , "Management ...
(Date:7/31/2014)... 31, 2014 Leelanau Peninsula’s newest winery, ... 2014 at 7788 East Horn Road in Lake Leelanau. Joining ... , Aurora Cellars is the 25th winery along the trail. ... popular wine tour events, making its trail event debut during ... , Owners David and Faye Mathia opened the boutique ...
(Date:7/31/2014)... Las Vegas, NV (PRWEB) July 31, 2014 ... personal trainer Tyler Bramlett and physical therapist expert Dr. James ... to shrink waistlines, fix back pain, relieve digestive issues, tone ... abs through a specific sequence of core exercises used to ... , After a quick 0-6 Pack Abs ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 ... hospitals in the U.S. including Florida Hospital Tampa, ... Acute Care, Florida Hospital North Pinellas, Florida Hospital ... Medical Center Sebring, Florida Hospital Heartland Medical Center ... & Health Networks list of Most Wired Hospitals ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure verification ... will be able to verify their patients before the ... guarantees their authenticity. This will help prospective patients ... information that has been verified to come from a ... Town to filter out fake patients who leave fraudulent ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... UPMC Health Plan announced it has,expanded both its ... its UPMC for Life Specialty Plan into Cameron, ... also announced the,expansion of its Medicare PPO (Preferred ... our footprint in Western Pennsylvania helps us continue ...
... poor physical function, , , TUESDAY, Jan. 22 (HealthDay News) -- If ... have a greater risk of declining physical function as you age, ... researchers report that people with the lowest blood levels of vitamin ... physical function when compared to people with the highest levels of ...
... STERIS Corporation,(NYSE: STE ) today announced that ... in the amount of $0.06 per common share. The,dividend ... at the close,of business on February 12, 2008., ... to provide a healthier today and,safer tomorrow through knowledgeable ...
... International effort should spot genes that help cause disease, ... The genomes of 1,000 people worldwide will be ... and medically relevant look at human genetic variation ever ... researchers on Tuesday, the 1000 Genomes Project will receive ...
... from the Monell Center and Tokyo University of Agriculture ... compounds from common foods that activate human bitter taste ... Biochemical and Biophysical Research Communications, provide a practical means ... in particular. , Identification of bitter taste ...
... nanotechnology, scientists from UCLA and Northwestern University have ... that is invisible to the immune system, a ... treatments for cancer and other diseases. , The ... ACS Nano, provides an example of the enormous ...
Cached Medicine News:Health News:UPMC Health Plan Expands Medicare and Special Needs Plan Into Additional Western Pennsylvania Counties 2Health News:Lack of Vitamin E Linked to Physical Decline 2Health News:Lack of Vitamin E Linked to Physical Decline 3Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3Health News:Project Will Map Genomes of 1,000 People Worldwide 2Health News:Food peptides activate bitter taste receptors 2Health News:Scientists use nanomaterials to localize and control drug delivery 2Health News:Scientists use nanomaterials to localize and control drug delivery 3
... INVACARE CHECK 02 PLUS CONCENTRATOR ANALYZER ... reports all the operating parameters necessary for ... O2 Plus ™, an efficient and cost-effective ... checks oxygen concentration (%), flow rate (L-min), ...
... the new Platinum 10 concentrator. The Platinum ... advantage you have come to expect from ... an attractive alternative to liquid systems. The ... 10 LPM for high flow patients, and ...
... QuietLife 5 Oxygen Concentrator is a low ... continuous flow oxygen for prescriptions up to ... the quietest running concentrator at <40 dBA, ... or caregivers. Concentrators are also an economical ...
... AirSep's LifeStyle Portable Oxygen Concentrator is ... At less than 10 lbs (4.5 kg), ... traveling, working, and highly active oxygen patient., ... and combining the technologies of both an ...
Medicine Products: